371 related articles for article (PubMed ID: 26381489)
1. Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
Bonanni P; Gabutti G; Demarteau N; Boccalini S; La Torre G
BMC Infect Dis; 2015 Sep; 15():377. PubMed ID: 26381489
[TBL] [Abstract][Full Text] [Related]
2. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
[TBL] [Abstract][Full Text] [Related]
5. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
6. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Kaló Z
BMC Public Health; 2012 Oct; 12():924. PubMed ID: 23110361
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
11. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
14. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
15. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial.
Lehtinen M; Apter D; Baussano I; Eriksson T; Natunen K; Paavonen J; Vänskä S; Bi D; David MP; Datta S; Struyf F; Jenkins D; Pukkala E; Garnett G; Dubin G
Vaccine; 2015 Mar; 33(10):1284-90. PubMed ID: 25593103
[TBL] [Abstract][Full Text] [Related]
17. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH
Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347
[TBL] [Abstract][Full Text] [Related]
18. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland.
Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Natunen K; Nieminen P; Paavonen J; Palmroth J; Petäjä T; Pukkala E; Vänskä S; Cheuvart B; Soila M; Bi D; Struyf F
Cancer Med; 2021 Nov; 10(21):7759-7771. PubMed ID: 34581025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]